KIT and systemic mastocytosis: In most patients with systemic mastocytosis (SM), including aggressive SM (ASM) and mast cell leukemia (MCL), neoplastic cells express the oncogenic C-KIT mutation D816V (24), which confers resistance to imatinib (25, 26).